The US FDA has approved cemdisiran (Livsayis), a small interfering RNA (siRNA) therapy, for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. It is the first and only approved siRNA therapy for gMG and the only FDA-approved treatment for the condition administered subcutaneously once every three months. Mechanism of Action Cemdisiran degrades complement C5 mRNA through RNA interference, reducing hepatic synthesis and circulating levels of C5 protein.

This inhibits terminal complement activation. Although its precise therapeutic mechanism in generalized myasthenia gravis remains unknown, its clinical effect is presumed to involve reduced deposition of the terminal complement complex C5b-9 at the neuromuscular junction. Clinical Evidence The efficacy of cemdisiran was evaluated in a 24-week, randomized, double-blind,โ€ฆ